BTCY - Earnings announcements

REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "The need for proactive chronic care manag

REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its second quarter of fiscal 2026, ended September 30, 2025. Leveraging best-in-class technology, strategic execution, and automation-driven operational efficiencies to maintain margins and expand its footprint, the company is delivering a clear path towards scalable, sustainable growth. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "This quarter

REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, e

FY25 revenue up 14.3% YOYFY25 margins improvement of 8.9% to 76.6%, from 69.3% in the prior year; Q4-FY25 margins improved to 80.4% as margin expansion forecasted to continueFY25 operating expenses lower by 24.5% YOYNegative EBITDA reduced by $5.7 million to $3.2 million – an improvement of 63.9%Positive Adjusted EBITDA of $438,260 in the fourth quarter of FY25 – first time in Company's history, highlighting Company's ability to achieve breakeven and EBITDA positive in the early part of its FY26 REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chroni

Company reports Q3-FY25 revenue grew by 21.7% YOY to $3.6 millionManagement continues to drive revenues and efficienciesCompany achieved positive cash flow on current operating basis, before paying interest, dividends and amortization for the second consecutive quarter, up 114.5% from the prior quarter; management expects to continue to see cash flows improveRecurring technology fees, existing and new customer sales see continued growthReduced SG&A to $2.38 million from $3.0 million, down 20.5% compared to the same period last yearGross margins continued to meet management expectations for improvement at 76.4%, a significant improvement from 72.9% for the same period last yearRecurring Techn

Company expects to report Q3-FY25 revenue growth of 22% from the corresponding prior year quarter to $3.6 million – an 11% increase sequentially from the immediately preceding quarterManagement continues to drive recurring revenue growth and efficienciesCompany to report positive cash flow for Q3-FY25 on current operating basis, before interest, dividends and amortizationCompany to report improved gross margins and operating results, as the Company nears its goal of achieving profitabilityManagement to release full financial results on Wednesday February 19th and host its Q3 Fiscal Year 2025 Financial Results Call on Thursday February 20th at 5:30 PM EST. REDWOOD CITY, Calif., Feb. 17, 202

Company achieved positive cash flow in September on a current operating basis, before paying interest, dividends and amortization; management expects to continue to see cash flows improveCompany reports Q2-FY25 revenue grew by 13% YOY to $3.3 millionGross margins continued to meet management expectations for improvement at 75.3%, a significant improvement from 69.1% for the same period last yearRecurring Technology Fee revenue comprised 94% of total revenue with a 79% gross profit percentageRecurring technology fees, additional device sales to existing customers see continued growthReduced SG&A to $2.25 million from $3.5 million, down 35.5% compared to the same period last yearNet loss attri

Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results

The Company shows continued progress towards cash-flow break even and profitabilityRecurring Technology Fee (SaaS) revenue - over 94% of total revenue with a 76% gross margin, which rose over 400 basis points and is expected to continue to trend higherGross margins improved significantly to 73.8 from 63.5% in the same period last year, and 59.6% 2 years earlierReduced SG&A to $3 million, down 16% compared to same period last yearOperating loss of $1.1 million, indicated efficiency gains of $1.2 million from the preceding year quarter - a 51.8% improvementGrowth in revenue of 6% YOY to $3.2 millionEBITDA and Adjusted EBITDA improved by 18.9% and 49.8%, respectively, from the corresponding per

ORLANDO, FL / ACCESSWIRE / July 26, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (NASDAQ:LOBO) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 27, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:LOBO EV: https://www.redchip.com/assets/access/lobo_accessNexalin: https://www.redchip.com/assets/access/nxl_accessIn an exclusive interview, Harry Schulman, an independent director of LOBO EV, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate u

ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Enlivex Therapeutics: https://www.redchip.com/assets/access/enlv_accessBiotricity: https://www.redchip.com/assets/access/btcy_accessOren Hershkovitz, Ph.D., CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update.

DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car

FY24 revenue up 25.2% YOYFY24 margins improved 1280 basis points to 69.3%, from 56.5% in the prior year; Q4-FY24 margins improved to 71.5%; margin expansion forecasted to continueFY24 operating expenses lower by 17.6% YOYNegative EBITDA reduced by $7.2 million - an improvement of 44.6% -- accelerating the Company's path to breakeven and EBITDA positive REDWOOD CITY, CA / ACCESSWIRE / June 27, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2024.Dr. Waqaas Al-Siddiq, Bi

ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (NASDAQ:BTTX) and Biotricity, Inc. (NASDAQ:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Better Therapeutics: https://www.redchip.com/assets/access/bttx_accessBiotricity: https://www.redchip.com/assets/access/btcy_accessFrank Karbe, CEO of Better Therapeutics, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Better Therape

Topline growth with better quality revenue mixIncrease in subscription revenue (fixed) vs usage based revenue (variable), reducing seasonality impact with more predictable revenueImproved marginsLower costs with improved selling expenseStronger path to breakevenREDWOOD CITY, CA / ACCESSWIRE / February 21, 2024 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the third quarter of fiscal 2024 year and (unaudited) ended December 31, 2023.Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "This quarter was marked by record ma

Company reports Q2-FY24 revenue grew by 21.4% YOY to $2.9 million; continuing to advance toward positive cashflowRecurring technology fees, customer device sales, remain on an upward trendReduced SG&A to $3.5 million, down 22% compared to same period last yearGross margins improve significantly to 69% from 54% compared to the same period last yearRecurring Technology Fee Revenue - comprised 94.5% of total revenue with a 70% gross marginNet loss decreased 21% to $3.9 millionManagement will host its Q2 Fiscal Year 2024 Financial Results Call on Tuesday, November 14th at 6:00 p.m. ETREDWOOD CITY, CA / ACCESSWIRE / November 14, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company")

REDWOOD CITY, CA / ACCESSWIRE / August 15, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, today announced its financial results for the first quarter of fiscal 2024 year ended June 30, 2023.Company reports Q1-FY24 revenue grew by 46.9% YOY to $3.0 million; continuing to advance toward positive cashflowRecurring technology fees and customer device sales, continue to trend higherReduced SG&A to $3.5 million, down 22% compared to same period last yearGross margins improve to 63.5% from 59.6% in the same period last yearRecurring Technology Fee revenue - over 90%

Company advancing toward positive cashflow likely by end of CY 2024Accelerating product sales, and customer re-order revenue,FY23 revenue rose 26% YOY to $9.64 million on 5% lower SG&A of $17.6 millionImproving gross margins currently at 57% despite reduced, loss-leader device pricing to boost recurring ‘Technology Fees,' lower customers' cost of entry, and capture market shareRecurring Technology Fee revenue - over 90% of total revenue with a 71% gross margin -- rose a robust 49% YOYNet loss decreased 35.4% to $19.5 millionCompany will host its FY23 Financial Results Call Friday, June 30 at 4:30 p.m. ETREDWOOD CITY, CA / ACCESSWIRE / June 30, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricit

Revenue Up 27.4% YOYEnviable 98% Customer Retention Rate Drives Subscription Recurring Rev GrowthTwo Major Distribution Agreements ImplementedNet Loss Narrowed by One Third as Company Targets Positive Cash FlowInvestor Teleconference Scheduled Today for 4:30 ETREDWOOD CITY, CA / ACCESSWIRE / February 14, 2023 / Biotricity Inc.(NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results and provided a business update for its third quarter of fiscal 2023 ended December 31, 2022.Commenting, Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "With our suite of state-of-the-art remote cardiac solutions now

REDWOOD CITY, CA / ACCESSWIRE / February 9, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it will host a conference call on Tuesday, February 14th, 2023 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 third quarter.Financial Results Conference CallAdditional details are available under the Investor Relations section of the Company's website: https://www.biotricity.com/investors/Event:Biotricity Fiscal 2023 Third Quarter Financial Results Conference CallDate:Tuesday, February 14, 2023Time:4:30 p.m. Eastern TimeLive Call:Webcast:1-877-405-1216 (U.S. Toll-Free) or 1-201-

Revenue totaled $2.4 million, up 14% sequentially quarter-over-quarterREDWOOD CITY, CA / ACCESSWIRE / November 14, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results and provided a business update for its fiscal 2023 second quarter ended September 30, 2022."We are pleased with our steady revenue growth year-over-year and sequentially for the fiscal second quarter. During this quarter, we have identified key drivers toward a path to profitability, potentially in the next 18 months, including new distribution partnerships with leading distribution networks. Our new partners

REDWOOD CITY, CA / ACCESSWIRE / November 1, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it will host a conference call on Monday, November 14, 2022 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 second quarter and provide a business update.Financial Results Conference CallAdditional details are available under the Investor Relations section of the Company's website: https://www.biotricity.com/investors/Event:Biotricity Fiscal 2023 Second Quarter Financial Results Conference CallDate:Monday, November 14, 2022Time:4:30 p.m. Eastern TimeLive Call:1-866-575-6539 (U.S.

REDWOOD CITY, CA / ACCESSWIRE / August 15, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022.Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, "We are pleased with our year-over-year revenue growth and ability to maintain gross margins at 60% as we begin to roll out our new Biotres and Bioheart products lines through our established network. Both new product offerings will complement the existing platform we have built through Bioflux to make the Biotricity ecosystem an all-in-one go-to solution for cardio

REDWOOD CITY, CA / ACCESSWIRE / August 5, 2022 /bbBiotricity Inc. (NYSE:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced it will host a conference call and webcast on Monday, August 15, 2022 at 4:30 p.m. ET to discuss its financial results for the fiscal first quarter 2023 and provide a business update. Additional details are available on the Company's website: https://www.biotricity.comConference Call and Webcast InformationEvent:Biotricity Fiscal First Quarter 2023 Financial Results Conference CallDate:Monday, August 15, 2022Time:4:30 p.m. Eastern TimeLive Call:1-888-220-8451 (U.S. Toll-Free) or 1-646-828-8193 (Internat

Management to host investor call on Tuesday February 15th at 4:15 pm ET93% YOY Revenue Gains to $1.93 MillionRevenue Outpaces SG&A Increase by 2.2xCash Position of $16.8 Million at Quarter End Is Highest EverContinues to Anticipate Full-Year Triple-Digit Revenue GrowthREDWOOD CITY, CA / ACCESSWIRE / February 14, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced financial results for its 2022 fiscal year's third quarter ended December 31, 2021.Q3-FY22 financial and operating highlights include:Revenue of $1.93 million, an increase of 93% year-over-year and sequentially 7% above the $1.8- mill

Management to host call on Tuesday, February 15th at 4:15pm ETSees Calendar-2022 as a breakout year with commercial launch of Bioheart and FDA clearance for BiotresREDWOOD CITY, CA / ACCESSWIRE / February 8, 2022 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, announced that it will release its financial results for the third quarter of fiscal 2022, ended December 31, 2021, on Monday, February 14, 2022, after the close of the market. Additionally, management will host a conference call and live webcast on Tuesday, February 15, 2022 at 4:15 p.m. EST to discuss the Company's financial results.To access the live

Management to Host Conference Call and Live Webcast at 5pm ETREDWOOD CITY, CA / ACCESSWIRE / November 2, 2021 / Biotricity, Inc. (NASDAQ:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will release its financial results for the second quarter ended September 30, 2021, on Thursday, November 4, 2021, after the close of the market.Additionally, management will host a conference call and live webcast for analysts and investors on November 4, 2021 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the company's financial results.To access the live call by phone, listeners may dial 720-543-0314 (local) or 800-309-1256 (toll free) and enter

Company's Momentum Continuing with Sales Growth, Recent Nasdaq listing and Successful Equity RaiseREDWOOD CITY, CA / ACCESSWIRE / September 8, 2021 / Biotricity, Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today reported its CEO Waqaas Al-Siddiq is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which will be available on-demand starting at 7:00 a.m. ET on Monday, September 13, 2021 (details provided below).Dr. Al-Siddiq will discuss the Company's continuing sales growth of its FDA-approved Bioflux® mobile cardiac telemetry (MCT) device which, as the Company previously announced, dr

REDWOOD CITY, CA / ACCESSWIRE / August 16, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, is pleased to provide financial results for its fiscal 2022 first quarter, which ended June 30, 2021. Full financial results will be posted on EDGAR later today. Biotricity's Q1 results maintain a trend of both sequential and year over year (YoY) growth, with revenue once again setting a new quarterly record.For Q1 Fiscal 2022, management is noting the following highlights:Q1 revenue of $1.76 million represented the 9th consecutive quarter of triple digit YoY growthQuarterly revenue increased 290% when comparing the first quarter of fiscal 2022 to